HC Wainwright Has Positive Estimate for SGMO FY2028 Earnings

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) – HC Wainwright increased their FY2028 earnings per share estimates for shares of Sangamo Therapeutics in a note issued to investors on Thursday, November 14th. HC Wainwright analyst P. Trucchio now anticipates that the biopharmaceutical company will earn $0.64 per share for the year, up from their prior estimate of $0.63. HC Wainwright has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Sangamo Therapeutics’ current full-year earnings is ($0.51) per share.

SGMO has been the topic of several other reports. Barclays raised their target price on shares of Sangamo Therapeutics from $3.00 to $9.00 and gave the stock an “overweight” rating in a research report on Thursday. StockNews.com upgraded Sangamo Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday.

Sangamo Therapeutics Stock Performance

Shares of SGMO opened at $2.05 on Friday. The company’s 50 day simple moving average is $1.33 and its 200 day simple moving average is $0.86. The company has a market capitalization of $427.67 million, a price-to-earnings ratio of -2.73 and a beta of 1.10. Sangamo Therapeutics has a 1 year low of $0.30 and a 1 year high of $3.18.

Institutional Investors Weigh In On Sangamo Therapeutics

A number of institutional investors have recently modified their holdings of the stock. XTX Topco Ltd increased its stake in Sangamo Therapeutics by 167.8% during the third quarter. XTX Topco Ltd now owns 103,716 shares of the biopharmaceutical company’s stock valued at $90,000 after purchasing an additional 64,981 shares during the last quarter. State Street Corp increased its holdings in shares of Sangamo Therapeutics by 28.0% in the 3rd quarter. State Street Corp now owns 664,621 shares of the biopharmaceutical company’s stock worth $576,000 after acquiring an additional 145,400 shares during the period. FMR LLC lifted its position in Sangamo Therapeutics by 16.5% in the 3rd quarter. FMR LLC now owns 544,003 shares of the biopharmaceutical company’s stock valued at $471,000 after purchasing an additional 77,032 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Sangamo Therapeutics by 5.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,103,326 shares of the biopharmaceutical company’s stock valued at $956,000 after purchasing an additional 57,125 shares during the period. Finally, Meritage Portfolio Management grew its position in Sangamo Therapeutics by 8.6% in the 3rd quarter. Meritage Portfolio Management now owns 85,000 shares of the biopharmaceutical company’s stock worth $74,000 after purchasing an additional 6,740 shares during the last quarter. Institutional investors and hedge funds own 56.93% of the company’s stock.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.